170 related articles for article (PubMed ID: 23289949)
1. Crystal structure of arylamine N-acetyltransferases: insights into the mechanisms of action and substrate selectivity.
Kubiak X; Dairou J; Dupret JM; Rodrigues-Lima F
Expert Opin Drug Metab Toxicol; 2013 Mar; 9(3):349-62. PubMed ID: 23289949
[TBL] [Abstract][Full Text] [Related]
2. Polymorphism p.Val231Ile alters substrate selectivity of drug-metabolizing arylamine N-acetyltransferase 2 (NAT2) isoenzyme of rhesus macaque and human.
Tsirka T; Boukouvala S; Agianian B; Fakis G
Gene; 2014 Feb; 536(1):65-73. PubMed ID: 24333853
[TBL] [Abstract][Full Text] [Related]
3. Arylamine N-acetyltransferases: characterization of the substrate specificities and molecular interactions of environmental arylamines with human NAT1 and NAT2.
Liu L; Von Vett A; Zhang N; Walters KJ; Wagner CR; Hanna PE
Chem Res Toxicol; 2007 Sep; 20(9):1300-8. PubMed ID: 17672512
[TBL] [Abstract][Full Text] [Related]
4. Arylamine N-acetyltransferases: from structure to function.
Sim E; Walters K; Boukouvala S
Drug Metab Rev; 2008; 40(3):479-510. PubMed ID: 18642144
[TBL] [Abstract][Full Text] [Related]
5. The Bacillus anthracis arylamine N-acetyltransferase ((BACAN)NAT1) that inactivates sulfamethoxazole, reveals unusual structural features compared with the other NAT isoenzymes.
Pluvinage B; Li de la Sierra-Gallay I; Kubiak X; Xu X; Dairou J; Dupret JM; Rodrigues-Lima F
FEBS Lett; 2011 Dec; 585(24):3947-52. PubMed ID: 22062153
[TBL] [Abstract][Full Text] [Related]
6. Arylamine N-acetyltransferases: a pharmacogenomic approach to drug metabolism and endogenous function.
Sim E; Pinter K; Mushtaq A; Upton A; Sandy J; Bhakta S; Noble M
Biochem Soc Trans; 2003 Jun; 31(Pt 3):615-9. PubMed ID: 12773167
[TBL] [Abstract][Full Text] [Related]
7. Arylamine N-acetyltransferases: structural and functional implications of polymorphisms.
Sim E; Lack N; Wang CJ; Long H; Westwood I; Fullam E; Kawamura A
Toxicology; 2008 Dec; 254(3):170-83. PubMed ID: 18852012
[TBL] [Abstract][Full Text] [Related]
8. Structure and mechanism of arylamine N-acetyltransferases.
Westwood IM; Kawamura A; Fullam E; Russell AJ; Davies SG; Sim E
Curr Top Med Chem; 2006; 6(15):1641-54. PubMed ID: 16918475
[TBL] [Abstract][Full Text] [Related]
9. Arylamine N-acetyltransferases: a structural perspective.
Zhou X; Ma Z; Dong D; Wu B
Br J Pharmacol; 2013 Jun; 169(4):748-60. PubMed ID: 23517104
[TBL] [Abstract][Full Text] [Related]
10. Divergence of cofactor recognition across evolution: coenzyme A binding in a prokaryotic arylamine N-acetyltransferase.
Fullam E; Westwood IM; Anderton MC; Lowe ED; Sim E; Noble ME
J Mol Biol; 2008 Jan; 375(1):178-91. PubMed ID: 18005984
[TBL] [Abstract][Full Text] [Related]
11. NMR-based model reveals the structural determinants of mammalian arylamine N-acetyltransferase substrate specificity.
Zhang N; Liu L; Liu F; Wagner CR; Hanna PE; Walters KJ
J Mol Biol; 2006 Oct; 363(1):188-200. PubMed ID: 16959263
[TBL] [Abstract][Full Text] [Related]
12. The pharmacogenetics of NAT: structural aspects.
Pompeo F; Brooke E; Kawamura A; Mushtaq A; Sim E
Pharmacogenomics; 2002 Jan; 3(1):19-30. PubMed ID: 11966400
[TBL] [Abstract][Full Text] [Related]
13. 3D model of human arylamine N-acetyltransferase 2: structural basis of the slow acetylator phenotype of the R64Q variant and analysis of the active-site loop.
Rodrigues-Lima F; Dupret JM
Biochem Biophys Res Commun; 2002 Feb; 291(1):116-23. PubMed ID: 11829470
[TBL] [Abstract][Full Text] [Related]
14. An approach to identifying novel substrates of bacterial arylamine N-acetyltransferases.
Brooke EW; Davies SG; Mulvaney AW; Pompeo F; Sim E; Vickers RJ
Bioorg Med Chem; 2003 Apr; 11(7):1227-34. PubMed ID: 12628650
[TBL] [Abstract][Full Text] [Related]
15. Structural basis of substrate-binding specificity of human arylamine N-acetyltransferases.
Wu H; Dombrovsky L; Tempel W; Martin F; Loppnau P; Goodfellow GH; Grant DM; Plotnikov AN
J Biol Chem; 2007 Oct; 282(41):30189-97. PubMed ID: 17656365
[TBL] [Abstract][Full Text] [Related]
16. Arylamine N-acetyltransferases--from drug metabolism and pharmacogenetics to identification of novel targets for pharmacological intervention.
Sim E; Fakis G; Laurieri N; Boukouvala S
Adv Pharmacol; 2012; 63():169-205. PubMed ID: 22776642
[TBL] [Abstract][Full Text] [Related]
17. Structure and regulation of the drug-metabolizing enzymes arylamine N-acetyltransferases.
Dupret JM; Rodrigues-Lima F
Curr Med Chem; 2005; 12(3):311-8. PubMed ID: 15723621
[TBL] [Abstract][Full Text] [Related]
18. Comparative Investigation of 15 Xenobiotic-Metabolizing
Garefalaki V; Papavergi MG; Savvidou O; Papanikolaou G; Felföldi T; Márialigeti K; Fakis G; Boukouvala S
Appl Environ Microbiol; 2021 Sep; 87(19):e0081921. PubMed ID: 34288706
[TBL] [Abstract][Full Text] [Related]
19. Structural and functional characterization of an arylamine N-acetyltransferase from the pathogen Mycobacterium abscessus: differences from other mycobacterial isoforms and implications for selective inhibition.
Cocaign A; Kubiak X; Xu X; Garnier G; Li de la Sierra-Gallay I; Chi-Bui L; Dairou J; Busi F; Abuhammad A; Haouz A; Dupret JM; Herrmann JL; Rodrigues-Lima F
Acta Crystallogr D Biol Crystallogr; 2014 Nov; 70(Pt 11):3066-79. PubMed ID: 25372695
[TBL] [Abstract][Full Text] [Related]
20. Cloning and molecular characterization of three arylamine N-acetyltransferase genes from Bacillus anthracis: identification of unusual enzymatic properties and their contribution to sulfamethoxazole resistance.
Pluvinage B; Dairou J; Possot OM; Martins M; Fouet A; Dupret JM; Rodrigues-Lima F
Biochemistry; 2007 Jun; 46(23):7069-78. PubMed ID: 17511472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
